Form 4: Director Michael Yang Receives Pacira Equity Grant
Statement of Changes in Beneficial Ownership
Pacira BioSciences director Michael J. Yang was granted 6,405 restricted stock units and 10,891 stock options.
Summary
- Director Michael J. Yang acquired 6,405 restricted stock units (RSUs) on June 10, 2026.
- Director Michael J. Yang was granted 10,891 stock options with an exercise price of $23.42.
- The total beneficial ownership for the director following these transactions is 19,798 shares of common stock.
- Both the RSUs and the stock options are subject to a one-year vesting period, becoming exercisable on June 10, 2027.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral administrative filing regarding standard director compensation, which does not signal a change in company strategy or financial health.
Positives
- Alignment of director interests with long-term shareholder value through equity-based compensation.
- Retention of key board leadership through multi-year vesting schedules.
Negatives
- Minor dilution of existing shareholders due to the issuance of new equity awards.
Risks
- Vesting is contingent upon the director remaining in continuous service with the issuer.
Future Outlook
The equity grants are subject to continued service requirements, with full vesting scheduled for June 10, 2027.
Industry Context
StockSavvy.ai notes that standard equity compensation for board members is a routine practice in the biotechnology sector to ensure director retention and alignment with corporate performance goals.
Comparison to Industry Standards
- The use of one-year cliff vesting for director equity is consistent with standard corporate governance practices for mid-cap biotechnology firms.
- The grant size is commensurate with typical non-employee director compensation packages for companies of similar market capitalization.
Stakeholder Impact
- Minimal impact on shareholders due to the standard nature of director compensation.
Next Steps
- Vesting of equity awards on June 10, 2027.
Key Dates
| Date | Description |
|---|---|
| 06/10/2026 | Transaction date for RSU and stock option grants. |
| 06/10/2027 | Vesting date for both RSUs and stock options. |
| 06/10/2036 | Expiration date for the granted stock options. |
| 06/12/2026 | Filing date of the Form 4. |
Keywords
Pacira BioSciences, PCRX, Form 4, Insider Trading, Equity Compensation, Director Compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.